Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology · Thyroid Eye Disease

The Long-Term Journey: Quality of Life and Care

At a Glance

The long-term management of Thyroid Eye Disease (TED) requires ongoing daily eye care, coordination between multiple specialists, and psychological support. Protecting your mental health and consistently using lubricating eye drops or nighttime protection are critical parts of your recovery.

Living with Thyroid Eye Disease (TED) is often described as a marathon rather than a sprint. While the initial “active” phase is intense, the long-term journey of survivorship requires a dedicated focus on your daily comfort, your mental well-being, and a coordinated team of specialists to support you [1].

Measuring Your Well-Being: The GO-QOL

Your doctor may ask you to complete the Graves’ Ophthalmopathy Quality of Life (GO-QOL) questionnaire [2]. This is a validated tool designed specifically for TED patients. It is divided into two main areas [3]:

  • Visual Functioning: How well you can perform daily tasks like reading, driving, or walking outdoors [4].
  • Appearance: How the changes in your eyes affect your self-confidence and your willingness to be in social settings or photos [5].

It is important to understand that feeling anxious or distressed about changes in your appearance is a recognized medical component of this disease, not a matter of vanity [6]. High scores on the appearance scale can be a sign to your doctor that you may benefit from rehabilitative surgery or psychological support [7].

The Psychological Toll

TED has a profound impact on mental health. Patients with TED have significantly higher rates of anxiety and depression than the general population [8]. The “changed face” can lead to a sense of lost identity and social withdrawal that often persists even after the physical inflammation has subsided [9][6]. Advocating for your mental health is just as critical as managing your thyroid levels; seeking counseling from professionals who understand the trauma of facial disfigurement can be a vital part of your recovery [1].

Long-Term Eye Care

Even in the stable, “inactive” phase, many survivors face chronic dry eye or exposure keratopathy (damage to the cornea because the eyelids don’t close fully) [10]. Managing this requires a proactive daily routine:

  • Lubrication: Using preservative-free artificial tears during the day and thick, protective ointments at night [11][12].
  • Nighttime Protection: Taping your eyes shut or wearing moisture-chamber goggles while you sleep can prevent the cornea from drying out and scarring [13].
  • Medicated Drops: In some cases, your doctor may prescribe anti-inflammatory drops like cyclosporine A to improve your natural tear production [14].

The Power of the Multidisciplinary Team

Because TED affects so many parts of your life, a “siloed” approach—where doctors don’t talk to each other—is often insufficient [15]. A multidisciplinary team is essential for long-term success [1]:

  • Endocrinologists focus on keeping your thyroid levels and antibodies stable to prevent relapses [16].
  • Ophthalmologists (specifically oculoplastic specialists) monitor your vision and perform the surgeries that restore function and appearance [15].
  • Mental Health Professionals provide the tools to cope with the emotional and social challenges of the disease [1].

By working with a coordinated team, you can ensure that every aspect of your health—physical, functional, and emotional—is addressed as you move forward [15][1].

Common questions in this guide

What is the GO-QOL questionnaire for Thyroid Eye Disease?
The Graves' Ophthalmopathy Quality of Life (GO-QOL) questionnaire is a tool doctors use to measure how TED affects your daily life. It evaluates your visual functioning and how changes in your appearance impact your confidence and social life.
How does Thyroid Eye Disease affect mental health?
The physical changes caused by TED can lead to significant emotional distress, a sense of lost identity, and social withdrawal. Patients often experience much higher rates of anxiety and depression, making mental health support a critical medical component of overall care.
How can I protect my eyes from drying out at night with TED?
To protect your corneas from drying out while you sleep, you can use thick, preservative-free lubricating ointments. If your eyelids do not close completely, your doctor may also recommend taping your eyes shut or wearing moisture-chamber goggles.
What is exposure keratopathy in Thyroid Eye Disease?
Exposure keratopathy is damage to the surface of the eye (the cornea) that happens when the eyelids cannot close fully, leaving the eye exposed to the air. It requires proactive daily care with lubricants and nighttime protection to prevent severe damage.
What kind of doctors should be on my TED care team?
Successful long-term management of TED requires a multidisciplinary team. This typically includes an endocrinologist to monitor thyroid levels, an oculoplastic ophthalmologist to manage eye health and surgeries, and mental health professionals to help you cope with emotional challenges.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can we use the GO-QOL questionnaire at each of my visits to track how my treatment is affecting my daily life and mental health?
  2. 2.Based on my lid position, am I at risk for exposure keratopathy, and what is the best nighttime routine to protect my corneas?
  3. 3.How will you coordinate my care between my endocrinologist and my eye specialist to ensure my thyroid stability is helping my eye symptoms?
  4. 4.Do you have a psychologist or social worker on your team who specializes in helping patients cope with chronic illness and facial changes?
  5. 5.Are there any new-onset symptoms, like intermittent blurring, that I should be reporting even if my disease is considered 'inactive'?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management.

    Scarabosio A, Surico PL, Singh RB, et al.

    Journal of personalized medicine 2024; (14(7)) doi:10.3390/jpm14070776.

    PMID: 39064030
  2. 2

    Quality of Life in Thyroid Eye Disease: A Systematic Review.

    Lee THB, Sundar G

    Ophthalmic plastic and reconstructive surgery 2020; (36(2)):118-126 doi:10.1097/IOP.0000000000001446.

    PMID: 31567783
  3. 3

    Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.

    Hoppe E, Lee ACH, Hoppe D, Kahaly GJ

    European thyroid journal 2021; (9(6)):313-320 doi:10.1159/000508071.

    PMID: 33718255
  4. 4

    Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.

    Zeng P, Fan SX, Li ZJ, et al.

    Journal of ophthalmology 2019; (2019()):7602419 doi:10.1155/2019/7602419.

    PMID: 31011452
  5. 5

    Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.

    Delfino LC, Zunino A, Sapia V, et al.

    Archives of endocrinology and metabolism 2017; (61(4)):374-381 doi:10.1590/2359-3997000000252.

    PMID: 28225858
  6. 6

    Quality of life and psychosocial well-being in thyroid eye disease in Japan: pre-teprotumumab national survey.

    Emoto S, Bushita Y, Nagase T, et al.

    Journal of the Endocrine Society 2026; (10(7)):bvag069 doi:10.1210/jendso/bvag069.

    PMID: 42245252
  7. 7

    Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.

    Kahaly GJ, Xi A, Barretto N, et al.

    Journal of the Endocrine Society 2025; (9(6)):bvaf063 doi:10.1210/jendso/bvaf063.

    PMID: 40303547
  8. 8

    Evaluation of Depression and Anxiety in a Diverse Population With Thyroid Eye Disease Using the Nationwide NIH All of Us Database.

    Lee TC, Radha-Saseendrakumar B, Delavar A, et al.

    Ophthalmic plastic and reconstructive surgery 2023; (39(3)):281-287 doi:10.1097/IOP.0000000000002318.

    PMID: 36727790
  9. 9

    Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.

    Cockerham KP, Padnick-Silver L, Stuertz N, et al.

    Ophthalmology and therapy 2021; (10(4)):975-987 doi:10.1007/s40123-021-00385-8.

    PMID: 34478126
  10. 10

    Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions.

    Shimazaki J

    Investigative ophthalmology & visual science 2018; (59(14)):DES7-DES12 doi:10.1167/iovs.17-23475.

    PMID: 30481800
  11. 11

    Systematic review of ocular surface treatments in the setting of thyroid eye disease.

    Wong AS, Chelnis JG

    Frontiers in ophthalmology 2024; (4()):1352355 doi:10.3389/fopht.2024.1352355.

    PMID: 38984136
  12. 12

    Management of ocular manifestations of autosomal recessive congenital ichthyosis 4B, harlequin type, in the perinatal period.

    Khalili A, Schear M, Greaves G, et al.

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2019; (23(6)):352-354 doi:10.1016/j.jaapos.2019.08.274.

    PMID: 31586585
  13. 13

    Efficacy of Simple Eye Ointment, Polyethylene Cover, and Eyelid Taping in Prevention of Ocular Surface Disorders in Critically Ill Patients: A Randomized Clinical Trial.

    Ahmadinejad M, Karbasi E, Jahani Y, et al.

    Critical care research and practice 2020; (2020()):6267432 doi:10.1155/2020/6267432.

    PMID: 32351735
  14. 14

    Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature.

    Rhee MK, Mah FS

    Clinical ophthalmology (Auckland, N.Z.) 2017; (11()):1157-1166 doi:10.2147/OPTH.S113437.

    PMID: 28790800
  15. 15

    Thyroid Eye Disease.

    Rashad R, Pinto R, Li E, et al.

    Life (Basel, Switzerland) 2022; (12(12)) doi:10.3390/life12122084.

    PMID: 36556449
  16. 16

    Thyroid-Stimulating Antibody/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves' Orbitopathy.

    Nakano M, Konishi H, Koshiba M

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2022; (28(10)):1050-1054 doi:10.1016/j.eprac.2022.07.007.

    PMID: 35870804

This page provides educational information about the long-term management and emotional impact of Thyroid Eye Disease. It is not a substitute for professional medical advice, diagnosis, or treatment from your endocrinologist or eye specialist.

Get notified when new evidence is published on thyrotoxic exophthalmos.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.